Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 plus CHOP/CHOEP in newly diagnosed peripheral T‑cell lymphoma (Ib/II)
CTR20234045Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zeprumetostat in peripheral T-cell lymphoma (PTCL), sponsored by Hengrui Therapeutics. Started Dec 2023; status: active.
02
Drugs
zeprumetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20234045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234045.